Figure 1.
Schematic of the DRINK trial design. Participants are randomised 1:1 to the high water (HW) or ad libitum (AW) water intake groups. Each participant in the HW group is given an individualised daily water prescription with urinary dilution targets consistent with vasopressin suppression. The AW group has more concentrated urinary targets. ADPKD, autosomal dominant polycystic kidney disease; uSG, urine specific gravity.